Patent: RE46323
✉ Email this page to a colleague
Summary for Patent: RE46323
Title: | Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses |
Abstract: | This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival. |
Inventor(s): | Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) |
Assignee: | Alexion Pharmaceuticals, Inc. (New Haven, CT) |
Application Number: | 14/080,457 |
Patent Claims: | see list of patent claims |
Details for Patent RE46323
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Centocor Ortho Biotech Products, L.p. | ORTHOCLONE OKT3 | muromanab-cd3 | Injection | 103463 | 09/14/1992 | ⤷ Try a Trial | 2027-07-25 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-07-25 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-07-25 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2027-07-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |